PT  - JOURNAL ARTICLE
AU  - Okamoto, Aikou
AU  - Glasspool, Rosalind M.
AU  - Mabuchi, Seiji
AU  - Matsumura, Noriomi
AU  - Nomura, Hiroyuki
AU  - Itamochi, Hiroaki
AU  - Takano, Masashi
AU  - Takano, Tadao
AU  - Susumu, Nobuyuki
AU  - Aoki, Daisuke
AU  - Konishi, Ikuo
AU  - Covens, Alan
AU  - Ledermann, Jonathan
AU  - Mezzazanica, Delia
AU  - Steer, Christopher
AU  - Millan, David
AU  - McNeish, Iain A.
AU  - Pfisterer, Jacobus
AU  - Kang, Sokbom
AU  - Gladieff, Laurence
AU  - Bryce, Jane
AU  - Oza, Amit
TI  - Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Ovary
AID  - 10.1097/IGC.0000000000000289
DP  - 2014 Nov 01
TA  - International Journal of Gynecologic Cancer
PG  - S20--S25
VI  - 24
IP  - Supp 3
4099  - http://ijgc.bmj.com/content/24/Supp_3/S20.short
4100  - http://ijgc.bmj.com/content/24/Supp_3/S20.full
SO  - Int J Gynecol Cancer2014 Nov 01; 24
AB  - Abstract Clear cell carcinoma of the ovary (CCC) is a histologic subtype of epithelial ovarian cancer with a distinct clinical behavior. There are marked geographic differences in the prevalence of CCC. The CCC is more likely to be detected at an early stage than high-grade serous cancers, and when confined within the ovary, the prognosis is good. However, advanced disease is associated with a very poor prognosis and resistance to standard treatment. Cytoreductive surgery should be performed for patients with stage II, III, or IV disease. An international phase III study to compare irinotecan/cisplatin and paclitaxel/carboplatin as adjuvant chemotherapy for stage IIV CCC has completed enrollment (GCIG/JGOG3017). Considering the frequent PIK3CA mutation in CCC, dual inhibitors targeting PI3K, AKT in the mTOR pathway, are promising. Performing these trials and generating the evidence will require considerable international collaboration.